Leena Tewari: Steering USV India’s Pharma Success
Leena Tewari, the reserved heiress of a pharmaceutical fortune, occupies the chairmanship of USV India, a prominent player in the pharmaceutical industry. Under her guidance, USV has solidified its position as a leader in diabetic and cardiovascular drugs, as well as a range of other pharmaceutical offerings.
Founding Legacy:
USV India was co-founded by Leena’s late father, Vithal Gandhi, in partnership with Revlon in 1961. Since its inception, the company has grown steadily, establishing a strong reputation for quality and innovation in the pharmaceutical sector.
Product Portfolio:
USV India’s focus on diabetic and cardiovascular drugs is evident in its diverse portfolio. The company specializes in biosimilar drugs, injectables, and active pharmaceutical ingredients, catering to the healthcare needs of a wide range of patients.
Strategic Acquisitions:
Under Leena Tewari’s leadership, USV India has pursued strategic acquisitions to expand its market presence and product offerings. The acquisition of German generics firm Juta Pharma in 2018 marked a significant milestone for the company, enhancing its global footprint and capabilities.
Operational Leadership:
While Leena Tewari chairs the company, the day-to-day operations are overseen by her husband, Prashant Tewari. A graduate of the Indian Institute of Technology and a mechanical engineer from Cornell, Prashant brings a wealth of technical expertise and strategic insight to USV India’s operations.
Next-Generation Leadership:
USV India’s commitment to continuity and innovation is evident in the appointment of Leena and Prashant’s daughter, Aneesha Gandhi Tewari, to the company’s board in August 2022. Aneesha, with a Ph.D. in molecular biology from MIT, represents the next generation of leadership, poised to drive USV India’s future growth and success.
Focus on Research and Development:
USV India places a strong emphasis on research and development, investing in cutting-edge technologies and scientific advancements to develop new and improved pharmaceutical solutions. This commitment to innovation ensures that the company remains at the forefront of medical advancements.
Legacy of Excellence:
Leena Tewari’s tenure at the helm of USV India is characterized by a dedication to excellence, quality, and patient care. Her strategic vision and leadership have propelled the company to new heights, earning it recognition as a leader in the pharmaceutical industry.
Conclusion:
Leena Tewari’s stewardship of USV India has been marked by a commitment to innovation, strategic growth, and a legacy of excellence. Under her leadership, the company has expanded its product portfolio, pursued strategic acquisitions, and invested in research and development to remain at the forefront of the pharmaceutical industry. With a focus on quality, innovation, and patient care, USV India continues to set the standard for pharmaceutical excellence in India and beyond.